Immunome, Inc.
IMNM
$15.67
-$0.82-4.97%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 16.74% | -13.76% | -35.50% | -0.62% | 62.73% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.74% | -13.76% | -35.50% | -0.62% | 62.73% |
| Cost of Revenue | 315.79% | 256.07% | 339.60% | 258.04% | 56.82% |
| Gross Profit | -484.75% | -412.60% | -919.28% | -610.80% | -53.67% |
| SG&A Expenses | 60.26% | 65.52% | 67.65% | 101.10% | 79.55% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 143.81% | 229.38% | 280.15% | 270.82% | 150.99% |
| Operating Income | -162.70% | -298.52% | -434.17% | -392.89% | -173.01% |
| Income Before Tax | 19.12% | 11.60% | -174.29% | -1,290.60% | -904.33% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 19.12% | 11.60% | -174.29% | -1,290.60% | -904.33% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 19.12% | 11.60% | -174.29% | -1,290.60% | -904.33% |
| EBIT | -162.70% | -298.52% | -434.17% | -392.89% | -173.01% |
| EBITDA | -163.31% | -298.63% | -437.26% | -396.07% | -173.41% |
| EPS Basic | 45.30% | 41.94% | -55.52% | -235.99% | -155.82% |
| Normalized Basic EPS | -72.46% | -77.41% | -63.35% | 1.06% | 31.68% |
| EPS Diluted | 45.24% | 41.88% | -55.64% | -235.64% | -155.60% |
| Normalized Diluted EPS | -72.46% | -77.41% | -63.35% | 1.06% | 31.68% |
| Average Basic Shares Outstanding | 73.88% | 120.99% | 195.47% | 340.31% | 242.29% |
| Average Diluted Shares Outstanding | 73.88% | 120.99% | 195.47% | 340.31% | 242.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |